ESC 365 - PCSK9 Inhibitors - State of the art

ESC Premium Access

PCSK9 Inhibitors - State of the art

Session: PCSK9 inhibitors - For the many or the few?

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor J. Armitage (Oxford, GB)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

9 presentations

2 followers

4 more presentations in this session

PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

Speaker: Doctor U. Kassner (Berlin, DE)

Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial

Speaker: Professor P. Sever (London, GB)

Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation

Speaker: Doctor S. Palee (Chiang Mai, TH)

Future hurdles in PCSK9 - Inhibition.

Speaker: Professor E. Stein (Cincinnati, US)

Access the full session

PCSK9 inhibitors - For the many or the few?

Speakers: Professor J. Armitage, Doctor U. Kassner, Professor P. Sever, Doctor S. Palee, Professor E. Stein

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

Related content

ESC Premium Access

Other post-COVID consequences: brain, kidneys and skeletal muscles.

27 August 2021

ESC Premium Access

Atrial fibrillation in heart failure: when to consider ablation therapy (and when it is too late).

27 August 2021

ESC Premium Access

Atrial fibrillation in heart failure: optimal pharmacological management.

27 August 2021

ESC 365 is supported by